Ezio Bonvini

Ezio Bonvini publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Ezio Bonvini sits on this spectrum.

Ezio Bonvini D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Ezio Bonvini sits on this spectrum.

Best Publications

• CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.

  Robbie G. Majzner;Johanna L. Theruvath;Anandani Nellan;Sabine Heitzeneder

  639
  Citations

• Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial.

  Nicole Sherry;William Hagopian;Johnny Ludvigsson;Sunil M Jain

  560
  Citations

• Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors

  Jeffrey B. Stavenhagen;Sergey Gorlatov;Nadine Tuaillon;Christopher T. Rankin

  521
  Citations

• Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

  Paul A. Moore;Wenjun Zhang;G. Jonah Rainey;Steve Burke

  473
  Citations

• Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity

  Deryk Loo;Ralph F. Alderson;Francine Z. Chen;Ling Huang

  378
  Citations

• Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells

  Kavita M. Dhodapkar;Jacob L. Kaufman;Marc Ehlers;Devi K. Banerjee

  356
  Citations

• Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.

  Syd Johnson;Stephen Burke;Ling Huang;Sergey Gorlatov

  332
  Citations

• Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.

  Hope S. Rugo;Seock Ah Im;Fatima Cardoso;Javier Cortés

  318
  Citations

• Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

  Geoffrey L. Uy;Ibrahim Aldoss;Matthew C. Foster;Peter H. Sayre

  307
  Citations

• Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties

  Jeffrey L Nordstrom;Sergey Gorlatov;Wenjun Zhang;Yinhua Yang

  299
  Citations

• Monoclonal antibodies capable of discriminating the human inhibitory Fcγ-receptor IIB (CD32B) from the activating Fcγ-receptor IIA (CD32A): biochemical, biological and functional characterization

  Maria-Concetta Veri;Sergey Gorlatov;Hua Li;Steve Burke

  275
  Citations

• Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.

  William Hagopian;Robert J. Ferry;Nicole Sherry;David Carlin

  260
  Citations

• Therapeutic Control of B Cell Activation via Recruitment of Fcγ Receptor IIb (CD32B) Inhibitory Function With a Novel Bispecific Antibody Scaffold

  Maria-Concetta Veri;Stephen Burke;Ling Huang;Hua Li

  207
  Citations

• A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.

  Gurunadh R. Chichili;Ling Huang;Hua Li;Steve Burke

  189
  Citations

• Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.

  Muneera Al-Hussaini;Michael P. Rettig;Julie K. Ritchey;Darja Karpova

  189
  Citations

• Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

  Unknown

  188
  Citations

• CD32B, the human inhibitory Fc-γ receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma

  Christopher T. Rankin;Maria-Concetta Veri;Sergey Gorlatov;Nadine Tuaillon

  171
  Citations

• Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.

  Juniper A Scribner;Jennifer G Brown;Thomas Son;Michael Chiechi

  149
  Citations

• Costimulation of T cell receptor/CD3-mediated activation of resting human CD4+ T cells by leukocyte function-associated antigen-1 ligand intercellular cell adhesion molecule-1 involves prolonged inositol phospholipid hydrolysis and sustained increase of intracellular Ca2+ levels.

  G A Van Seventer;E Bonvini;H Yamada;A Conti

  146
  Citations

• Tumor Necrosis Factor {alpha} (TNF-{alpha}) Activates Jak1/Stat3-Stat5B Signaling through TNFR-1 in Human B Cells

  Sebastiano Miscia;Marco Marchisio;Alfredo Grilli;Valentina Di Valerio

  136
  Citations